PREVAX: A Phase I Clinical Trial of an EGF-Based Vaccine in Moderate-to-Severe COPD Patients.
Jenysbel de la C Hernandez ReyesOrestes Santos MoralesLaura Hernandez MorenoPedro Pablo Pino AlfonsoElia Neninger VinagerasJulia Lilliam Knigths MontalvoAliuska Aguilar SosaAmnely Gonzalez MoreraPatricia Lorenzo Luaces-AlvarezYadira Aguilar VenegasMayelin Troche ConcepciónLoipa Medel PérezYanela Santiesteban GonzálezLázara García FernándezLorena Regueiro RodríguezAmparo Macías AbrahanMayrel Labrada MonKalet LeonDanay Saavedra HernándezTania Crombet RamosPublished in: Vaccines (2024)
The EGF-based vaccine was immunogenic and provoked an EGF exhaustion in patients with moderate-to-severe COPD. Depleting EGF might result in a meaningful increase in FEV1, with good tolerability. The current results provide new avenues to treat chronic inflammatory lung diseases associated with EGFR aberrant signaling.
Keyphrases
- growth factor
- clinical trial
- chronic obstructive pulmonary disease
- end stage renal disease
- small cell lung cancer
- lung function
- high intensity
- open label
- newly diagnosed
- ejection fraction
- chronic kidney disease
- early onset
- oxidative stress
- prognostic factors
- epidermal growth factor receptor
- double blind
- randomized controlled trial
- study protocol
- patient reported outcomes